Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : to Deliver 220,000 COVID-19 Antibody Cocktail Doses to EU

09/21/2021 | 11:37pm EDT


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
10/20ELI LILLY AND : FCA And AKS Claim Founded On Free Pharmaceutical Product Education Dismiss..
AQ
10/19ELI LILLY AND : Tirzepatide results published in The Lancet show superior A1C and body wei..
PR
10/19Eli Lilly and Company Provides Tirzepatide Results
CI
10/18ELI LILLY AND : Declares Q4 Dividend of $0.85 a Share, Payable Dec. 10 to Shareholders of ..
MT
10/18ELI LILLY AND : Lilly Declares Fourth-Quarter 2021 Dividend
PR
10/18Eli Lilly and Company Declares Dividend for the Fourth Quarter of 2021, Payable on Dece..
CI
10/14ELI LILLY AND : Releases Updated Data From Phase 3 Breast Cancer Trial
MT
10/14ELI LILLY AND : Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Dat..
PR
10/14Eli Lilly and Company Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial ..
CI
10/13AGILENT TECHNOLOGIES : Eli Lilly Get FDA's OK for Assay to Identify Early Breast Cancer
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 366 M - -
Net income 2021 6 489 M - -
Net Debt 2021 11 548 M - -
P/E ratio 2021 34,1x
Yield 2021 1,35%
Capitalization 221 B 221 B -
EV / Sales 2021 8,50x
EV / Sales 2022 8,24x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 243,75 $
Average target price 269,42 $
Spread / Average Target 10,5%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY44.37%220 979
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
MERCK & CO., INC.-0.79%205 421